A multicenter phase II study of TP-38 in those patients with glioblastoma multiforme who have recurred or progressed after previous resection and radiation therapy and are scheduled for gross total resection
Latest Information Update: 02 Nov 2021
At a glance
- Drugs TP 38 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 20 May 2011 Company added as reported by ClinicalTrials.gov.
- 04 Jan 2008 Status changed from recruiting to completed.
- 02 Sep 2005 New trial record.